AEGR was WAY OVERBOUGHT, on the misguided assumption that ISIS would get rejected
WRONG! Hope you were smart enough to sell before the vote, stock now pulling back a whopping $2 from the high. Genzyme says to you longs, NOT SO FAST, PEOPLE! And ISIS is a HUGELY better investment long-term, over 25 drugs in pipeline, 6 are currently in Phase 2. Lots of potential lottery tickets in there, folks!
I agree as a long term hold ISIS is better (I held it for two years), but AEGR is a better short term hold through FDA approval. There is still a reasonable chance ISIS will be required to provide additional cancer and liver tox data before approval by the FDA. A 9-6 vote with one panelist stating his was a "weak yes" is going to weigh heavily on the FDA, since they have Lopitimade which only had 2 dissenters. If they delay approval of Mipo there is still a viable drug with better efficacy available to this patient population. There is also the possibility that Sanofi/Genzyme or other large pharma will buy AEGR. In the meantime, for docs who have these patients, which drug is prescribed is a no-brainer.